Skip to main content
. 2018 Jan 3;9(9):8415–8426. doi: 10.18632/oncotarget.23865

Figure 4. Comparative 3-years survival analysis of stromal and tumoral inflammation.

Figure 4

Overall 3-years survival analysis for CD45, CD11b, CD3, MMP-9 and COX-2 was performed separately for stroma and tumor (A) High CD45 expression in the stroma, but not in the tumor (first row), was associated with lower survival (p = 0.047). In contrast, high CD11b infiltration in the tumor nests, not in the stroma, showed an association with lower survival (p = 0.043). CD3 and MMP-9 expression had no significant influence on patients´ survival. Interestingly, high COX-2 expression in the tumor, not in the stroma, was associated with a significantly lower survival rate (p = 0.009). (B) The combination of high stromal CD45 and high tumoral COX-2 was associated with earlier death (p = 0.037). For this analysis patients with simultaneous high stromal CD45 and high tumoral COX-2 expression were included in the “both high” group.